Oct 12 (Reuters) - U.S. health regulators on Friday widened the approved use of Celgene Corp's breast cancer drug Abraxane to include treatment for non-small cell lung cancer, the most common form of lung cancer.
Abraxane is currently approved to treat patients with metastatic breast cancer who have failed to respond to other treatments. Celgene hopes to win approval to market it for several other types of cancer, including pancreatic cancer and melanoma.
Celgene acquired Abraxane when it bought Abraxis BioScience in 2010 for $2.9 billion, which some investors considered an excessively high price.
The drug combines the cancer chemotherapy paclitaxel with a protein called albumin, which Celgene believes helps deliver a greater amount of chemotherapy to cancer cells with fewer side effects.
Abraxane's peak annual lung cancer sales could eventually reach $110 million, according to a research note from Barclays on Thursday.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.
- Get Livefyre
- FAQ
